Adial Pharmaceuticals (ADIL) News Today $0.65 -0.05 (-7.24%) Closing price 04:00 PM EasternExtended Trading$0.65 0.00 (-0.62%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Adial Pharmaceuticals appoints new COO Tony GoodmanMarch 23, 2025 | uk.investing.comEquities Analysts Set Expectations for ADIL Q1 EarningsMarch 22, 2025 | americanbankingnews.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deAdial Pharmaceuticals expects cash to fund operations into 2H of 2025March 4, 2025 | markets.businessinsider.comAdial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | globenewswire.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 26, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | markets.businessinsider.comAdial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulationFebruary 25, 2025 | markets.businessinsider.comAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | globenewswire.comAdial awarded patent covering genetic approach to alcoholism by USPTOFebruary 19, 2025 | markets.businessinsider.comAdial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug DependenciesFebruary 19, 2025 | globenewswire.comAdial Pharmaceuticals awarded new U.S. patent on genotype-specific treatmentFebruary 12, 2025 | markets.businessinsider.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersFebruary 12, 2025 | finance.yahoo.comAdial Pharmaceuticals secures new patent for addiction treatmentFebruary 12, 2025 | msn.comAdial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related DisordersFebruary 12, 2025 | globenewswire.comAdial Pharmaceuticals Completes Pharmacokinetics Study of AD04, Prepares for FDA End-of-Phase 2 InteractionJanuary 31, 2025 | nasdaq.comAdial completes key study for alcohol disorder drugJanuary 29, 2025 | msn.comAdial Pharmaceutical Announces Positive Findings From AD04-103 Pharmacokinetics StudyJanuary 29, 2025 | markets.businessinsider.comAdial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderJanuary 29, 2025 | globenewswire.comAdial Pharma stock hits 52-week low at $0.72 amid market challengesJanuary 28, 2025 | msn.comAdial Pharmaceuticals files to sell 5.0M shares of common stock for holdersDecember 21, 2024 | markets.businessinsider.comAdial granted U.S. patent for treatment of alcohol, drug dependenceDecember 3, 2024 | markets.businessinsider.comEXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype CombinationsDecember 3, 2024 | finance.yahoo.comAdial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype CombinationsDecember 3, 2024 | globenewswire.comAdial Pharmaceuticals Advances AD04 with Promising Study ResultsNovember 19, 2024 | markets.businessinsider.comMaxim Group Sticks to Their Hold Rating for Adial Pharmaceuticals (ADIL)November 16, 2024 | markets.businessinsider.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 15, 2024 | finanznachrichten.deAdial Pharmaceuticals (NASDAQ:ADIL) Stock, Short Interest ReportNovember 15, 2024 | benzinga.comEXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use DisorderNovember 15, 2024 | finance.yahoo.comAdial Pharmaceuticals initiated with a Buy at Rodman & RenshawNovember 15, 2024 | markets.businessinsider.comRodman & Renshaw Initiates Coverage of Adial Pharmaceuticals (ADIL) with Buy RecommendationNovember 15, 2024 | msn.comAdial Pharmaceuticals expects cash to fund operations into second half of 2025November 13, 2024 | markets.businessinsider.comAdial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | markets.businessinsider.comAdial Pharmaceuticals Approves Strategic Changes at Annual MeetingNovember 13, 2024 | markets.businessinsider.comAdial Pharmaceuticals Appoints New Chief Financial OfficerNovember 6, 2024 | markets.businessinsider.comAdial Pharmaceuticals Appoints Vinay Shah as Chief Financial OfficerNovember 5, 2024 | globenewswire.comAdial Pharmaceuticals to Present at the 2024 ThinkEquity ConferenceOctober 23, 2024 | globenewswire.comEXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder CandidateOctober 18, 2024 | finance.yahoo.comAdial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of RecoveryOctober 16, 2024 | finance.yahoo.comAdial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comMaxim Group Keeps Their Hold Rating on Adial Pharmaceuticals (ADIL)September 21, 2024 | markets.businessinsider.comAdial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderSeptember 19, 2024 | globenewswire.comAdial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deAdial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comADIL Stock Earnings: Adial Pharmaceuticals Reported Results for Q2 2024August 14, 2024 | markets.businessinsider.comAdial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04August 13, 2024 | finance.yahoo.comEXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use DisorderAugust 13, 2024 | msn.comBone Therapeutics SA (BT1.SG)August 10, 2024 | sg.finance.yahoo.comEXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4August 7, 2024 | msn.com Remove Ads Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Media Mentions By Week ADIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADIL News Sentiment▼0.840.78▲Average Medical News Sentiment ADIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADIL Articles This Week▼61▲ADIL Articles Average Week Remove Ads Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IN8bio News Mannatech News Cellectar Biosciences News Senti Biosciences News Edesa Biotech News BioAtla News Chemomab Therapeutics News Bullfrog AI News Elevation Oncology News NextCure News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADIL) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.